Document is current
Any future updates will be listed below
-
Authors
Faux, Pierre https://orcid.org/0000-0003-4486-6327
Ding, Li
Ramirez-Aristeguieta, Luis Miguel https://orcid.org/0000-0002-0961-5824
Chacón-Duque, J. Camilo https://orcid.org/0000-0003-0715-1947
Comini, Maddalena https://orcid.org/0000-0002-9559-8839
Mendoza-Revilla, Javier
Fuentes-Guajardo, Macarena
Jaramillo, Claudia
Arias, William https://orcid.org/0000-0002-2543-4855
Hurtado, Malena
Villegas, Valeria
Granja, Vanessa
Barquera, Rodrigo https://orcid.org/0000-0003-0518-4518
Everardo-Martínez, Paola https://orcid.org/0000-0002-7629-1022
Quinto-Sánchez, Mirsha
Gómez-Valdés, Jorge https://orcid.org/0000-0001-6996-2732
Villamil-Ramírez, Hugo
Silva de Cerqueira, Caio C.
Hünemeier, Tábita
Ramallo, Virginia
Gonzalez-José, Rolando
Schüler-Faccini, Lavinia
Bortolini, Maria-Cátira
Acuña-Alonzo, Victor
Canizales-Quinteros, Samuel
Poletti, Giovanni
Gallo, Carla
Rothhammer, Francisco
Rojas, Winston
Schmid, Annina B. https://orcid.org/0000-0001-7759-0211
Adhikari, Kaustubh https://orcid.org/0000-0001-5825-4191
Bennett, David L. https://orcid.org/0000-0002-7996-2696
Ruiz-Linares, Andrés https://orcid.org/0000-0001-8372-1011
- License Information
-
More Information
Article History
Received: 24 February 2023
Accepted: 25 August 2023
First Online: 10 October 2023
Competing interests
: D.L.B. has acted as a consultant in the last 2 years for AditumBio, Biointervene, Combigene, LatigoBio, GSK, Ionis, Lexicon therapeutics, Lilly, Neuvati, Olipass, Orion, Replay, SC Health Managers, Third Rock ventures and Vida Ventures on behalf of Oxford University Innovation. He has received research funding from Lilly and Astra Zeneca. He has received an industrial partnership grant from the BBSRC and AstraZeneca. The other authors declare no competing interests.
